Evaluation of Expression of Lrba and Ctla-4 Proteins in Common Variable Immunodeficiency Patients Publisher Pubmed



Salami F^{1, 2} ; Fekrvand S² ; Yazdani R² ; Shahkarami S^{2, 3, 4} ; Azizi G⁵ ; Bagheri Y⁶ ; Delavari S² ; Shariati S^{1, 2} ; Mahdaviani SA⁷ ; Nabavi M¹² ; Shirkani A¹³ ; Abolhassani H^{8, 9} ; Samadi M^{1, 10, 11} ; Aghamohammadi A² Show Affiliations
Source: Immunological Investigations Published:2022

Abstract

Common variable immunodeficiency (CVID) is a primary immunodeficiency disease with a heterogeneous genetic background. Lipopolysaccharide-responsive beige-like anchor (LRBA), as well as cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), have important regulatory roles in the immune responses. Here, we have investigated the expression of LRBA and CTLA-4 proteins in CVID patients with at least one presentation of early-onset occurrence, autoimmunity, or enteropathy. In this study, 20 newly diagnosed CVID patients without infection only phenotype, and ten healthy individuals were enrolled. The expressions of LRBA and CTLA-4 proteins were assessed by western blotting and flow cytometry, respectively. The patients were divided into two groups of autoimmunity-positive (11 cases) and autoimmunity-negative (9 patients). LRBA and CTLA-4 expressions were significantly lower in autoimmune-positive patients than in healthy individuals (P = .03 and P = .03, respectively). Autoimmune-negative patients had lower expression of LRBA and CTLA-4 than the control group, although it was not significant. There was a positive correlation between the expressions of LRBA and CTLA-4 in both groups of patients (P < .05). Furthermore, the highest frequency of LRBA (85.7%) and CTLA-4 (71.4%) defects was detected in those with concomitant presence of autoimmunity, enteropathy, and early-onset occurrence. Concurrent presence of autoimmunity, enteropathy, and early-onset occurrence in CVID patients could be indicative of a lack of expression in LRBA and CTLA-4 proteins. This could be helpful in early diagnosis and initiation of appropriate treatment in these patients prior to genetic confirmation. © 2020 Taylor & Francis Group, LLC.